Go To Global Site
Welcome to UCB in the United States

Oct

20

UCB to license its AI technology that improves identification of Osteoporosis to ImageBiopsy Lab

Oct

16

Update on U.S. FDA Review of Biologics License Application (BLA) for bimekizumab

Sep

29

New Bimekizumab Two-Year Data in Moderate to Severe Plaque Psoriasis Presented at the 30th European Academy of Dermatology and Venereology Congress

Aug

30

UCB Announces BRIVIACT® (brivaracetam) CV Now FDA-Approved to Treat Partial-Onset Seizures in Pediatric Patients One Month of Age and Older

Aug

07

New Two-Year Data Showed Bimekizumab Maintained High Levels of Skin Clearance in Patients with Moderate to Severe Plaque Psoriasis

Apr

28

UCB Announces PDUFA Date for Bimekizumab

Apr

23

"The New England Journal of Medicine" Publishes Results from Two Bimekizumab Phase 3 Studies in Moderate to Severe Plaque Psoriasis

Apr

23

UCB to Present 12 Abstracts on Bimekizumab at AAD VMX 2021

UCB to Present 12 Abstracts on Bimekizumab at AAD VMX 2021 

Apr

16

UCB Showcases New Research at the 73rd American Academy of Neurology Annual Meeting to Demonstrate Broad Neurology Leadership and Future Portfolio

Feb

25

UCB - Sustaining Growth, Now and Into the Future